Meta-analysis
Year of publication
Number of patients
Number of studies
OR (CI 95 %)
OR (CI 95 %)
OR (CI 95 %)
–
–
–
–
Aprotinin versus tranexamic acid
Aprotinin versus aminocaproic acid
Aprotinin versus placebo
Howell [12]abc
2013
15,528
88
0.73 (0.45–1.12)
0.88 (0.50–2.13)
1.11 (0.75-1.53)
Hutton [14]ac
2012
14,773
82
0.64 (0.41–0.99)
0.79 (0.47–1.55)
0.99 (0.72–1.36)
Hutton [14]abc
2012
41,350
93
0.71 (0.50–0.98)
0.60 (0.43–0.87)
0.91 (0.71–1.16)
Henry [13]ad
2011
17,136
85
1.35 (0.94–1.93)
1.51 (0.99–2.30)
0.81 (0.63–1.06)
Table 16.2
Meta-analyses of aprotinin-related studies—mortality and number of patients
Meta-analysis |
Number of patients |
Number of studies |
Number of patients/deaths (%) |
RR 95 % CI | |||
---|---|---|---|---|---|---|---|
– |
– |
– |
Aprotinin |
TXA |
EACA |
Control |
– |
Howell [12]abc |
15,528 |
88 |
6,284/177 (2.81 %) |
3,048/62 (2.03 %) |
1,309/44 (3.36 %) |
4,887/110 (2.25 %) |
NS |
Henry [13]d (cochrane): |
– |
– |
– |
– |
– |
– |
– |
A versus control |
8,876 |
63 |
4,889/116 (2.37 %) |
– |
– |
3,987/104 (2.6 %) |
0.81 (0.63 to 1.06) |
TXA versus Control |
2,917 |
30 |
– |
1,478/15 (1.01 %) |
– |
1,439/28 (1.94 %) |
0.60 (0.33–1.10) |
EACA versus Control |
922 |
8 |
– |
– |
504/10 (1.98 %)
![]() Full access? Get Clinical Tree![]() ![]() ![]() |